Abstract: An ultrasound imaging method, including: using a probe to perform real-time ultrasound imaging on a site to be imaged so as to generate an ultrasound image of the site to be imaged; receiving a location selection on the ultrasound image from an input device; acquiring blood flow information at the selected location on the ultrasound image; and on the basis of the blood flow information at the selected location, in real time, controlling the input device to generate force feedback. Other embodiments of the present application further provide an ultrasound imaging system and a non-transitory computer-readable medium.

Abstract: A method for authentication of charging a vehicle includes: transmitting a vehicle identification number and at least one vehicle state information from the vehicle to a charging pile after plugging a charging gun of the charging pile into the vehicle; sending, by the vehicle, its vehicle state information to a remote server; sending, by the charging pile, the vehicle identification number and the vehicle state information derived from the vehicle to the remote server; comparing the vehicle state information sent by the vehicle with the vehicle state information sent by the charging pile for the vehicle identification number in the remote server; and passing the authentication if at least one item in the vehicle state information matches. An additional safety mechanism is realized based on the existing communication standards, and ensures safety in a simple and reliable manner without modifying the charging connection assembly.

Abstract: The present disclosure relates, according to some embodiments, to compositions and analysis of RNA (e.g., dephosphorylated oligoribonucleotides) including, for example, natural and/or synthetic RNAs. A composition may comprise, for example, an endoribonuclease having an amino acid sequence that (i) corresponds to an amino acid sequence of a first species (e.g., Homo sapiens, Escherichia coli, Aspergillus oryzae, Momordica charantia, Pyrococcus furiosus, Cucumis sativus, and Sus scrofa) or (ii) is a non-naturally occurring sequence; and/or an RNA end repair enzyme having an amino acid sequence that (i) corresponds to an amino acid sequence of a species other than the first species (e.g., a bacterial species or a bacteriophage species) or (ii) is a non-naturally occurring sequence.

Abstract: Substrates having a textured surface that can maintain or improve droplet mobility in both the Cassie and Wenzel states include a textured surface and a conformal lubricant layer thereover. The textured surface can include a plurality of raised first elements and a plurality of second elements thereon and the conformal lubricant layer over the plurality of raised first elements and covering the plurality of second elements. The plurality of raised first elements can have an average height of between 0.5 ?m and 500 ?m, and the plurality of second elements can have an average height of between 0.01 ?m and 10 ?m. Such substrates can be prepared by texturing a surface of a substrate with a plurality of raised first elements and a plurality of second elements thereon; optionally silanizing the textured surface and applying a lubricant layer over the plurality of raised first elements and between the plurality of second elements.

Abstract: The present disclosure relates, according to some embodiments, to compositions and analysis of RNA (e.g., dephosphorylated oligoribonucleotides) including, for example, natural and/or synthetic RNAs. A composition may comprise, for example, an endoribonuclease having an amino acid sequence that (i) corresponds to an amino acid sequence of a first species (e.g., Homo sapiens, Escherichia coli, Aspergillus oryzae, Momordica charantia, Pyrococcus furiosus, Cucumis sativus, and Sus scrofa) or (ii) is a non-naturally occurring sequence; and/or an RNA end repair enzyme having an amino acid sequence that (i) corresponds to an amino acid sequence of a species other than the first species (e.g., a bacterial species or a bacteriophage species) or (ii) is a non-naturally occurring sequence.

Abstract: Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.

Abstract: Provided herein is a method for chemically capping polynucleotides having a 5? monophosphate. In some embodiments the method may comprise: combining an activated nucleoside 5? mono- or poly-phosphate with a population of polynucleotides that comprises polynucleotides having a 5? monophosphate, to produce a reaction mix; and incubating the reaction mix to produce reaction products that comprise a polynucleotide and a 5? nucleoside cap, linked by a 5? to 5? polyphosphate linkage. The chemical capping method described herein can be incorporated into a variety of cDNA synthesis methods.

Abstract: A combination pharmaceutical composition used for the treatment of small cell lung cancer, comprising: (i) compound I or a pharmaceutically acceptable salt thereof; and (ii) at least one second treatment drug, the chemical name of compound I being 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.

Abstract: Provided herein is a method for making an cDNA library, comprising adding an affinity tag-labeled GMP to the 5? end of targeted RNA species in a sample by optionally decapping followed by incubating the sample with an affinity tag-labeled GTP and a capping enzyme, enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag, reverse transcribing the enriched RNA to produce a population of cDNAs, and adding a tail to the 3? end of the population of cDNAs using a terminal transferase, to produce an cDNA library.

Abstract: Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.

Abstract: A tumor immunotherapy composition based on modified cells, in particular antigen-presenting cells activated by means of attenuated Listeria monocytogenes, a preparation method therefor and an application thereof. Attenuated Listeria monocytogenes carrying a specific antigen plasmid is used to activate antigen-presenting cells, thereby activating WIC antigen presenting properties and a series of cellular immune responses in vivo so as to achieve the purpose of anti-tumor therapy. The described technical solution may specifically activate macrophages and/or dendritic cells, thereby eliciting a series of specific anti-tumor immune responses. The operation process does not require genetic modification of autologous cells, is not limited by tumor type, and operations of the overall process are simple, easy-to-implement and reproducible.

Abstract: Methods, compositions and kits for selectively altering and detecting modified cytosine residues are provided.

Abstract: Provided herein is a method for making an cDNA library, comprising adding an affinity tag-labeled GMP to the 5? end of targeted RNA species in a sample by optionally decapping followed by incubating the sample with an affinity tag-labeled GTP and a capping enzyme, enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag, reverse transcribing the enriched RNA to produce a population of cDNAs, and adding a tail to the 3? end of the population of cDNAs using a terminal transferase, to produce an cDNA library.

Abstract: 5-methylpyrimidine oxygenases and their use in the modification of nucleic acids are described.

Abstract: This disclosure describes, among other things, compositions, kits and methods for identifying to 5-hydroxymethylcytosine (5hmC) in eukaryotic genomic DNA. The compositions and methods utilize a PvuRts1I family enzyme for digesting eukaryotic genomic DNA suspected of containing 5hmC or 5-formylcytosine (5fC) modified nucleotides providing an end of the DNA with a two base overhang suitable for ligating an adapter at a fixed distance 3? from an 5hmC. Random fragmentation of the genomic DNA can generate a blunt end suitable for attaching a second adapter. The DNA can be sequenced and 5hmC and 5fC residues identified and located at a defined position in the eukaryotic genome. An enrichment step may be used that utilizes a chemoselective agent capable of being selectively added to DNA containing 5hmC. An example is a glucosyltransferase and a glucosyltransferase substrate comprising a chemo-selective group.

Abstract: Methods, compositions and kits for selectively altering and detecting modified cytosine residues are provided.

Abstract: Methods, compositions and kits for selectively altering and detecting modified cytosine residues are provided.

Abstract: Nucleic acids comprising ?-glucosaminyloxy-5-methylcytosine; compositions, kits and methods of producing the nucleic acids using a glycosyltransferase; and methods of using the nucleic acids are described.

Abstract: Nucleic acids comprising ?-glucosaminyloxy-5-methylcytosine; compositions, kits and methods of producing the nucleic acids using a glycosyltransferase; and methods of using the nucleic acids are described.

Abstract: 5-methylpyrimidine oxygenases and their use in the modification of nucleic acids are described.